OBJECTIVES: Fear of progression is one of the most prevalent symptoms in cancer patients. The aim of this study was to validate the 12-item short version of the Fear of Progression Questionnaire (FoP-Q-SF). METHODS: A total of 1083 breast cancer patients were recruited by the Hamburg Cancer Register to fill out various questionnaires (response rate 67 %). RESULTS: Estimates of reliability were high (Cronbach's alpha = .87). The original one-factor structure was replicated. We used the HADS, the PCL-C, and the SF-8, among others, to validate the FoP-Q-SF. Significant positive correlations were found for fear of progression, anxiety and intrusion (r > .60) as well as for avoidance, hyperarousal and depression (r > or = .49). Moderate to high (negative) correlations were observed with health-related quality of life, in particular with the mental health dimensions (r > or = .48). Patients with cancer recurrence reported significant higher levels of fear of progression (p < .001). CONCLUSIONS: The short form of the Fear of Progression Questionnaire appears to be a reliable and valid instrument which can be recommended for further use in research and clinical care.
OBJECTIVES: Fear of progression is one of the most prevalent symptoms in cancerpatients. The aim of this study was to validate the 12-item short version of the Fear of Progression Questionnaire (FoP-Q-SF). METHODS: A total of 1083 breast cancerpatients were recruited by the Hamburg Cancer Register to fill out various questionnaires (response rate 67 %). RESULTS: Estimates of reliability were high (Cronbach's alpha = .87). The original one-factor structure was replicated. We used the HADS, the PCL-C, and the SF-8, among others, to validate the FoP-Q-SF. Significant positive correlations were found for fear of progression, anxiety and intrusion (r > .60) as well as for avoidance, hyperarousal and depression (r > or = .49). Moderate to high (negative) correlations were observed with health-related quality of life, in particular with the mental health dimensions (r > or = .48). Patients with cancer recurrence reported significant higher levels of fear of progression (p < .001). CONCLUSIONS: The short form of the Fear of Progression Questionnaire appears to be a reliable and valid instrument which can be recommended for further use in research and clinical care.
Authors: Sophie Elisabeth Groß; Anika Nitzsche; Tristan D Gloede; Lena Ansmann; Richard Street; Holger Pfaff; Melanie Neumann; Markus Wirtz; Walter Baumann; Stephan Schmitz; Nicole Ernstmann Journal: Support Care Cancer Date: 2014-09-25 Impact factor: 3.603
Authors: S Sarkar; A Scherwath; L Schirmer; F Schulz-Kindermann; K Neumann; M Kruse; A Dinkel; S Kunze; F Balck; N Kröger; U Koch; A Mehnert Journal: Bone Marrow Transplant Date: 2014-07-07 Impact factor: 5.483
Authors: J Hefner; M Kapp; K Drebinger; A Dannenmann; H Einsele; G-U Grigoleit; H Faller; H Csef; S Mielke Journal: Bone Marrow Transplant Date: 2014-01-20 Impact factor: 5.483
Authors: Linda Kwakkenbos; Linda M Willems; Frank H J van den Hoogen; Wim G J M van Lankveld; Hanneke Beenackers; Toon F van Helmond; Eni S Becker; Cornelia H M van den Ende Journal: J Clin Psychol Med Settings Date: 2014-12
Authors: N Ernstmann; M Neumann; O Ommen; M Galushko; M Wirtz; R Voltz; M Hallek; H Pfaff Journal: Support Care Cancer Date: 2009-03-13 Impact factor: 3.603
Authors: Peter Herschbach; Katrin Book; Andreas Dinkel; Petra Berg; Sabine Waadt; Gabriele Duran; Ursula Engst-Hastreiter; Gerhard Henrich Journal: Support Care Cancer Date: 2009-10-29 Impact factor: 3.603